Sponsored by
Neurology. 2006 Apr 25;66(8):1258-60. Related Articles, Links
Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF.
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. wpope@mednet.ucla.edu
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
PMID: 16636248 [PubMed - in process]